Business Description
CDT Equity Inc. is a clinical-stage pharmaceutical company focused on developing treatments for autoimmune conditions and unexplained male infertility. Its two lead drug candidates, AZD1656 and AZD5904, have each completed Phase I clinical trials across several indications, including kidney transplant rejection, thyroid disease, eye inflammation, and premature labor. The company works with Agility Life Sciences, a specialist drug development partner, to create new oral solid-dose formulations. Founded in 2019 and headquartered in Naples, Florida, the company was previously called Conduit Pharmaceuticals Inc. before renaming itself in August 2025.
